MedTrace Logo

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

NCT06571591 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 606

Last updated 2026-05-15

No results posted yet for this study

Summary

Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.

Conditions

  • T2DM

Interventions

DRUG

Empagliflozin

tablet, QD, oral administration

DRUG

Metformin

tablets, oral administration

DRUG

CT-L03 Group 2

tablets, QD, oral administration

DRUG

Placebo

tablets, QD, oral administration

DRUG

CT-L03 Group 1

tablets, QD, oral administration

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-27
Primary Completion
2026-04-16
Completion
2026-05-04

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06571591 on ClinicalTrials.gov